fashion -WSS

fashion

author：explore 2025-09-29 05:12:46 - browse：9886

Three boxes of Breyanzi on a dark blue background — biotech coverage from STAT — The FDA is looking into adverse events involving a number of CAR-T therapies, including Breyanzi. Illustration: STAT; Source: Business Wire

The Food and Drug Administration said Tuesday that it is investigating whether CAR-T therapy, which uses genetically modified white blood cells to attack tumors, can in rare cases cause lymphoma, a blood cancer.

“Although the overall benefits of these products continue to outweigh their potential risks for their approved uses, FDA is investigating the identified risk of T cell malignancy with serious outcomes, including hospitalization and death, and is evaluating the need for regulatory action,” the agency said in a statement.

The agency noted that it is investigating reports of T cell lymphoma, including cancer cells carrying the engineered T cells, in patients who received CAR-T therapy. Experts in the field, which has produced multiple approved products to treat blood cancer, expressed surprise and puzzlement at the announcement, saying that they had not previously seen data about the risk.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： UnitedHealth quietly bought dozens of outpatient centers

leisure time

hotspot

WSS

First medicine developed to treat MASH expected to be approved soon

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Precocious puberty in girls comes with mental health risks

How to bring more disabled researchers into academia

How Vertex's cystic fibrosis drug is changing patients' lives

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

focus

fashion

hotspot

Virginia high school admissions case could be legal follow

EpiPen alternative approval delay highlights citizen petition issue

Drug repurposing or repositioning? The language matters

Changes to biosimilar regulatory framework must prioritize patients

Supreme Court strikes down use of affirmative action

Microbiome research is starting to find links to chronic diseases

DIEP, the 'gold standard' of breast reconstruction, is under threat

Drug for rare kidney disease narrowly misses mark in clinical trial

In Memoriam: Notable people who died in 2023

The drug industry has found itself all alone in Washington

hotspot

Novo Nordisk obesity pill bests Wegovy in early trial

Medical student insurance fails on mental health care coverage

With psoriasis trial ahead, Alumis raises $259 million

Why are Kaiser Permanente staff considering a strike?

How to bring more disabled researchers into academia

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

hotspot

leisure time

hotspot

focus